Marksans Pharma Stock Scales New 52-Week Peak at Rs 351: Key Reasons Behind the Surge

Published: 24 September 2026 at 9:48 AM IST

Marksans Pharma Share Price was in focus on 24 September 2026 at 9:48 AM IST after the stock touched a fresh 52-week high of Rs 350.75 and later closed at Rs 343.9, down 1.02% from the previous close of Rs 347.45. The company’s market capitalisation stood at Rs 15,072.23 crore. The data confirms a one-year high for Marksans Pharma Ltd. (MARKSANS), while the latest close shows the stock ended below the session peak. Based on the supplied figures, the event is relevant because it places Marksans Pharma Share Price among the day’s notable stock news items in the Indian stock market, but the data does not establish a company-specific reason for the move.

The session opened at Rs 347.25, moved between Rs 341.95 and Rs 350.75, and finished at Rs 343.9. Turnover was Rs 1.94 crore. The fresh 52-week high, together with the company’s market cap and valuation metrics, gives investors a concrete snapshot of Marksans Pharma Share Price Today. Univest is tracking this Marksans Pharma Stock News event as a price-led development supported by verified market data.

Marksans Pharma Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 343.9
Previous Close	Rs 347.45
Today's Move	Rs -3.55 (-1.02%)
Open	Rs 347.25
High	Rs 350.75
Low	Rs 341.95
Turnover	Rs 1.94 crore
Market Capitalisation	Rs 15,072.23 crore

Marksans Pharma Ltd. (MARKSANS) traded at Rs 343.9 versus the previous close of Rs 347.45, a fall of 1.02%. The stock opened at Rs 347.25, reached a high of Rs 350.75 and touched a low of Rs 341.95.

Marksans Pharma Share Price Today shows a session that first extended to a fresh 52-week high of Rs 350.75 and then settled lower at Rs 343.9. The stock opened at Rs 347.25, compared with the previous close of Rs 347.45, and moved within a range of Rs 341.95 to Rs 350.75. That means the latest close was Rs 3.55 below the previous close and Rs 6.85 below the day’s high. Turnover of Rs 1.94 crore provides the value of shares transacted during the session. In simple terms, Marksans Pharma Share Price has marked a one-year high and then ended below the peak, making the day notable for stock price news rather than for any stated company-specific trigger.

For readers following Marksans Pharma Share Price Live, the session matters because it records a fresh yearly high in the same session even though the closing price was lower than the peak. That makes the day’s price action the central development in Marksans Pharma Stock News.

Marksans Pharma Ltd. (MARKSANS) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 15,072.23 crore
P/E Ratio	30.47x
P/B Ratio	4.95x
ROE	15.31%
ROCE	21.1%
EPS	Rs 11.4
Book Value Per Share	Rs 70.16
Dividend Yield	0.26%

Marksans Pharma Ltd. (MARKSANS) fundamental metrics show P/E 30.47x, P/B 4.95x, ROE 15.31%, ROCE 21.1%. These figures provide context only and are not a buy or sell signal.

Marksans Pharma Ltd. has a market capitalisation of Rs 15072.23 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 30.47x, P/B at 4.95x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 15.31% and ROCE of 21.1%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 11.4, book value per share of Rs 70.16, dividend yield of 0.26%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 32.33x, median ROE of 11.69%, median ROCE of 13.32%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	30.47x
Benchmark Median P/E	32.33x
Benchmark Average P/E	50.13x
Benchmark P/E Range	3.48x to 762.66x
Company P/B Ratio	4.95x
Benchmark Median P/B	2.95x
Company ROE	15.31%
Benchmark Median ROE	11.69%
Company ROCE	21.1%
Benchmark Median ROCE	13.32%
Company Market Capitalisation	Rs 15,072.23 crore
Benchmark Median Market Cap	Rs 745.38 crore

Marksans Pharma Ltd. (MARKSANS) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Marksans Pharma Ltd. (MARKSANS) has a P/E ratio of 30.47x, which is below the benchmark median of 32.33x, a difference of -5.75%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Marksans Pharma Ltd. (MARKSANS) has a ROE of 15.31%, which is above the benchmark median of 11.69%, a difference of +30.97%. Marksans Pharma Ltd. (MARKSANS) has a ROCE of 21.1%, which is above the benchmark median of 13.32%, a difference of +58.41%.

Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Natco Pharma Ltd.	NATCOPHARM	14,596.56	13.11	1.61	16.3	17.16
Concord Biotech Ltd.	CONCORDBIO	16,013.08	59.23	7.87	13.54	18.04
Alembic Pharmaceuticals Ltd.	APLLTD	16,518.18	23.93	2.84	12.35	11.74
Astrazeneca Pharma India Ltd.	ASTRAZEN	16,773	98.89	18.55	23.02	31.24
Sudeep Pharma Ltd.	SUDEEPPHRM	13,540.85	74.17	14.66	25.37	28.5

Marksans Pharma Ltd. (MARKSANS) has a P/E ratio of 30.47x compared with the displayed peer median of 59.23x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 15.31% compares with a peer median of 16.3% across the companies shown in the table. ROCE stood at 21.1% versus the displayed peer median of 18.04%, providing a capital-efficiency comparison. Marksans Pharma Ltd. (MARKSANS) has a market capitalisation of Rs 15,072.23 crore. Among the 5 peers shown, 3 have a larger market capitalisation.

Why Investors Are Watching Marksans Pharma

• Marksans Pharma Share Price touched a fresh 52-week high of Rs 350.75 in the session.
• The stock later closed at Rs 343.9 after opening at Rs 347.25 and trading between Rs 341.95 and Rs 350.75.
• Market capitalisation stood at Rs 15,072.23 crore.
• Valuation shows a P/E of 30.47, P/B of 4.95, ROE of 15.31% and ROCE of 21.1%.
• In the same-industry benchmark, the company’s P/E is below the median, while ROE and ROCE are above the median.

About Marksans Pharma

Marksans Pharma Ltd. (MARKSANS) is part of the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied data identifies the company by name and market listing context, and its current share price event has placed Marksans Pharma Share Price in the spotlight for stock news readers. The article’s verified figures capture the company through market capitalisation, valuation, earnings and return ratios rather than through broad assumptions.

Track Marksans Pharma Share Price on Univest

Use Marksans Pharma Ltd. (MARKSANS) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.

Univest tracks Marksans Pharma Share Price, Marksans Pharma Share Price Today, Marksans Pharma Stock News and Marksans Pharma Share News in one place. Readers can monitor live price updates, 52-week levels, valuation ratios, shareholding pattern, financial results and sector comparisons through the Univest stock page.

Frequently Asked Questions

What happened to Marksans Pharma Share Price today?

Ans. Marksans Pharma Share Price touched a fresh 52-week high of Rs 350.75 and then closed at Rs 343.9, down 1.02% from the previous close of Rs 347.45. The session also recorded turnover of Rs 1.94 crore.

Did Marksans Pharma set a new 52-week high?

Ans. Yes. Marksans Pharma Share Price reached Rs 350.75, which is the fresh 52-week high in the supplied data. The stock later ended below that peak, but the yearly high remains the key price event.

What is Marksans Pharma market capitalisation?

Ans. Marksans Pharma’s market capitalisation was Rs 15,072.23 crore. That places the company above the same-industry median market cap of Rs 745.38 crore and close to the industry average of Rs 14,295.86 crore.

How is Marksans Pharma valued on earnings and book value?

Ans. Marksans Pharma trades at a P/E of 30.47 and a P/B of 4.95. EPS is Rs 11.4 and book value per share is Rs 70.16, which gives a clear earnings and accounting-value reference.

How do Marksans Pharma profitability ratios compare with the industry?

Ans. Marksans Pharma reports ROE of 15.31% and ROCE of 21.1%. Both are above the same-industry median and average, which places the company ahead of the benchmark central tendency on these profitability measures.

Which peers are useful for Marksans Pharma Share Price comparison?

Ans. The supplied peers include Natco Pharma, Concord Biotech, Alembic Pharmaceuticals, Astrazeneca Pharma India and Sudeep Pharma. They provide a useful comparison set for Marksans Pharma Share Price on P/E, P/B, ROE, ROCE and market cap.